SHANGHAI MICURX PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Shanghai MicuRx Pharmaceutical Co., Ltd. specializes in the discovery, development, and commercialization of innovative anti-infective therapeutics designed to combat multi-drug resistant (MDR) bacterial pathogens. The company’s primary focus is the development of next-generation antibiotics with improved safety profiles. Its lead commercial product, contezolid (MRX-I), is an oxazolidinone antibiotic indicated for complex skin and soft tissue infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The research pipeline includes MRX-4, a prodrug of contezolid, and MRX-8, a novel therapeutic targeting Gram-negative "superbugs." By utilizing a proprietary drug discovery platform, the company aims to provide effective treatment options for serious infectious diseases while reducing common toxicities associated with traditional antibiotic classes.